Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Allergan plc (NYSE:AGN)

231.09
Delayed Data
As of 4:03pm ET
 +0.54 / +0.23%
Today’s Change
195.50
Today|||52-Week Range
340.34
-26.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Generic
MARKET CAP
$91.2B

Company Description

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. The firm offers products under the following brands: BOTOX, Juvederm, Linzess, Namenda, Restasis, Latisse, Teflaro, Lo Loestrin Fe, Bystolic, DORYX, Saphris, Fetzima, Namenda XR, Namzaric, Viberzi, Viibryd, Alphagan, LUMIGAN, ESTRACE Cream, Rapaflo, Asacol, DELZICOL, Zenpep, Avycaz, and Dalvance. Its brand portfolio delivers treatments that address unmet medical needs in therapeutic categories such as dermatology and aesthetics; central nervous system; eye care; women health and urology; gastroenterology and cystic fibrosis; and cardiovascular and infectious disease. The company was founded on October 1, 2012 and is headquartered in Dublin, Ireland.

Contact Information

Allergan Plc
Clonshaugh Business & Tech. Park
Dublin Dublin D17 E400
P:3538622617000
Investor Relations:
(862) 261-7152

Employees

Shareholders

Other institutional47.15%
Mutual fund holders42.82%
Individual stakeholders0.20%

Top Executives

Brenton L. SaundersPresident, Chief Executive Officer & Director
Robert A. StewartChief Operating Officer
Maria Teresa HiladoChief Financial Officer
C. David NicholsonChief Research & Development Officer
Jonathon KellermanGlobal Chief Compliance Officer & Executive VP